These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 34678650)

  • 1. Drug-eluting immune checkpoint blockade antibody-nanoparticle conjugate enhances locoregional and systemic combination cancer immunotherapy through T lymphocyte targeting.
    Francis DM; Manspeaker MP; Archer PA; Sestito LF; Heiler AJ; Schudel A; Thomas SN
    Biomaterials; 2021 Dec; 279():121184. PubMed ID: 34678650
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Local and Targeted Delivery of Immune Checkpoint Blockade Therapeutics.
    Han X; Li H; Zhou D; Chen Z; Gu Z
    Acc Chem Res; 2020 Nov; 53(11):2521-2533. PubMed ID: 33073988
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Blockade of immune checkpoints in lymph nodes through locoregional delivery augments cancer immunotherapy.
    Francis DM; Manspeaker MP; Schudel A; Sestito LF; O'Melia MJ; Kissick HT; Pollack BP; Waller EK; Thomas SN
    Sci Transl Med; 2020 Sep; 12(563):. PubMed ID: 32998971
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overcoming T Cell Exhaustion in Tumor Microenvironment via Immune Checkpoint Modulation with Nano-Delivery Systems for Enhanced Immunotherapy.
    Huang X; Zhang W
    Small Methods; 2024 Aug; 8(8):e2301326. PubMed ID: 38040834
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advancing cancer immunotherapy through siRNA-based gene silencing for immune checkpoint blockade.
    Choi Y; Seok SH; Yoon HY; Ryu JH; Kwon IC
    Adv Drug Deliv Rev; 2024 Jun; 209():115306. PubMed ID: 38626859
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lymphatic immunomodulation using engineered drug delivery systems for cancer immunotherapy.
    Manspeaker MP; Thomas SN
    Adv Drug Deliv Rev; 2020; 160():19-35. PubMed ID: 33058931
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting immune checkpoints in hematological malignancies.
    Salik B; Smyth MJ; Nakamura K
    J Hematol Oncol; 2020 Aug; 13(1):111. PubMed ID: 32787882
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Cancer Nanovaccine for Co-Delivery of Peptide Neoantigens and Optimized Combinations of STING and TLR4 Agonists.
    Baljon JJ; Kwiatkowski AJ; Pagendarm HM; Stone PT; Kumar A; Bharti V; Schulman JA; Becker KW; Roth EW; Christov PP; Joyce S; Wilson JT
    ACS Nano; 2024 Mar; 18(9):6845-6862. PubMed ID: 38386282
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmaceutical targeting Th2-mediated immunity enhances immunotherapy response in breast cancer.
    Chen Y; Sun J; Luo Y; Liu J; Wang X; Feng R; Huang J; Du H; Li Q; Tan J; Ren G; Wang X; Li H
    J Transl Med; 2022 Dec; 20(1):615. PubMed ID: 36564797
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Photothermal therapies to improve immune checkpoint blockade for cancer.
    Balakrishnan PB; Sweeney EE; Ramanujam AS; Fernandes R
    Int J Hyperthermia; 2020 Dec; 37(3):34-49. PubMed ID: 33426992
    [TBL] [Abstract][Full Text] [Related]  

  • 11. T cell-mediated targeted delivery of tadalafil regulates immunosuppression and polyamine metabolism to overcome immune checkpoint blockade resistance in hepatocellular carcinoma.
    Wang X; Zhang Q; Zhou J; Xiao Z; Liu J; Deng S; Hong X; Huang W; Cai M; Guo Y; Huang J; Wang Y; Lin L; Zhu K
    J Immunother Cancer; 2023 Feb; 11(2):. PubMed ID: 36813307
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparing syngeneic and autochthonous models of breast cancer to identify tumor immune components that correlate with response to immunotherapy in breast cancer.
    Lal JC; Townsend MG; Mehta AK; Oliwa M; Miller E; Sotayo A; Cheney E; Mittendorf EA; Letai A; Guerriero JL
    Breast Cancer Res; 2021 Aug; 23(1):83. PubMed ID: 34353349
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neoadjuvant immune checkpoint blockade triggers persistent and systemic T
    Blomberg OS; Kos K; Spagnuolo L; Isaeva OI; Garner H; Wellenstein MD; Bakker N; Duits DEM; Kersten K; Klarenbeek S; Hau CS; Kaldenbach D; Raeven EAM; Vrijland K; Kok M; de Visser KE
    Oncoimmunology; 2023; 12(1):2201147. PubMed ID: 37089449
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adaptive antitumor immune response stimulated by bio-nanoparticle based vaccine and checkpoint blockade.
    Bai X; Zhou Y; Yokota Y; Matsumoto Y; Zhai B; Maarouf N; Hayashi H; Carlson R; Zhang S; Sousa A; Sun B; Ghanbari H; Dong X; Wands JR
    J Exp Clin Cancer Res; 2022 Apr; 41(1):132. PubMed ID: 35392977
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vectorized Treg-depleting αCTLA-4 elicits antigen cross-presentation and CD8
    Semmrich M; Marchand JB; Fend L; Rehn M; Remy C; Holmkvist P; Silvestre N; Svensson C; Kleinpeter P; Deforges J; Junghus F; Cleary KL; Bodén M; Mårtensson L; Foloppe J; Teige I; Quéméneur E; Frendéus B
    J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35058324
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cancer immunotherapy with PI3K and PD-1 dual-blockade via optimal modulation of T cell activation signal.
    Isoyama S; Mori S; Sugiyama D; Kojima Y; Tada Y; Shitara K; Hinohara K; Dan S; Nishikawa H
    J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34446575
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Utilizing chemotherapy-induced tumor RNA nanoparticles to improve cancer chemoimmunotherapy.
    Su L; Pan W; Li X; Zhou X; Ma X; Min Y
    Acta Biomater; 2023 Mar; 158():698-707. PubMed ID: 36563773
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Photo-induced crosslinked and anti-PD-L1 peptide incorporated liposomes to promote PD-L1 multivalent binding for effective immune checkpoint blockade therapy.
    Lee Y; Song S; Yang S; Kim J; Moon Y; Shim N; Yoon HY; Kim S; Shim MK; Kim K
    Acta Pharm Sin B; 2024 Mar; 14(3):1428-1440. PubMed ID: 38487005
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mild hyperthermia promotes immune checkpoint blockade-based immunotherapy against metastatic pancreatic cancer using size-adjustable nanoparticles.
    Yu Q; Tang X; Zhao W; Qiu Y; He J; Wan D; Li J; Wang X; He X; Liu Y; Li M; Zhang Z; He Q
    Acta Biomater; 2021 Oct; 133():244-256. PubMed ID: 34000465
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting of focal adhesion kinase enhances the immunogenic cell death of PEGylated liposome doxorubicin to optimize therapeutic responses of immune checkpoint blockade.
    Zhang B; Li N; Gao J; Zhao Y; Jiang J; Xie S; Zhang C; Zhang Q; Liu L; Wang Z; Ji D; Wu L; Ren R
    J Exp Clin Cancer Res; 2024 Feb; 43(1):51. PubMed ID: 38373953
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.